Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Dimerix Limited ( (AU:DXB) ) has shared an update.
Dimerix Limited announced the quotation of 4,039,351 ordinary fully paid securities on the Australian Securities Exchange (ASX) under the code DXB, effective June 24, 2025. This move reflects the company’s strategic efforts to enhance its market presence and potentially increase liquidity, which could have positive implications for its stakeholders and overall industry positioning.
The most recent analyst rating on (AU:DXB) stock is a Buy with a A$1.33 price target. To see the full list of analyst forecasts on Dimerix Limited stock, see the AU:DXB Stock Forecast page.
More about Dimerix Limited
Dimerix Limited operates in the biotechnology industry, focusing on developing innovative therapies for unmet medical needs. The company primarily engages in the research and development of pharmaceutical products, aiming to address significant health challenges.
Average Trading Volume: 3,279,289
Technical Sentiment Signal: Strong Buy
Current Market Cap: A$335M
See more insights into DXB stock on TipRanks’ Stock Analysis page.